Sigma Capital Management’s AbbVie ABBV Stock Holding History

Sigma Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-255,000	Closed	-$13.1M	–	1
2014 Q1	$13.1M	Buy	255,000 +130,000	+104%	+$6.57M	0.67%	52
2013 Q4	$6.6M	Buy	+125,000	New	+$6.14M	0.37%	64
2013 Q3	–	Sell	-150,000	Closed	-$6.2M	–	278
2013 Q2	$6.2M	Buy	+150,000	New	+$6.56M	0.28%	90

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Sigma Capital Management's ABBV Position: Q2 2014 in Review

Sigma Capital Management sold out of AbbVie (ABBV) in Q2 2014, closing a stake of 255,000 shares — an estimated $13.1M sold.

Sigma Capital Management first reported a position in ABBV in Q2 2013 and held it in 3 quarters. The position peaked at $13.1M in Q1 2014. 1,457 funds tracked by Wall St. Rank hold ABBV as of Q2 2014.

Sigma Capital Management reported no remaining AbbVie position as of Q2 2014 after selling out during the quarter.
Sigma Capital Management sold 255,000 AbbVie shares in Q2 2014, an estimated $13.1M.
Sigma Capital Management first reported a position in AbbVie in Q2 2013 and held it in 3 quarters.
Sigma Capital Management's AbbVie position peaked at $13.1M in Q1 2014.
1,457 funds tracked by Wall St. Rank held AbbVie as of Q2 2014.

Based on Sigma Capital Management's 13F filing for Q2 2014.